Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Artrya Limited (AYA.AX)
AUD5.82
+0.14 (+2.46%)
AU ASX Healthcare Medical - Healthcare Information Services
Address
1257 Hay Street 6005
West Perth, WA, AU
West Perth, WA, AU
CEO
John Konstantopoulos
Website
artrya.com
IPO
2021-11-25
ISIN AU0000182412
Description
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD5.82
+0.14 (+2.46%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
545.9K
Beta
0.64
Float Shares
86.34M
Free Float %
75.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.22% | +3.34% | +24.69% | +45.59% | +50.91% | +5.10% | +551.32% | +2,202.33% | +223.53% | +223.53% | +223.53% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
5.82
DCF (Unlevered)
0.17
-97.0%
DCF (Levered)
0.12
-98.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
116.79
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Healthcare Information Services: +14.2%—
-
EPS growth Medical - Healthcare Information Services: +43.1%+0.0% Q4'25: -95.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-63,707.1% Q4'25: -78,221.4% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-59,350.0% Q4'25: -91,835.7% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%-157.1% Q4'25: -388.9% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+17.4% Q4'25: +60.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-0.04× Q4'25: -0.01× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 3 Rev. Ana. 3 EPS Ana. |
Jun 2027 3 Rev. Ana. 3 EPS Ana. |
Jun 2028 3 Rev. Ana. 2 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
Jun 2030 2 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 1.00M (-100.0%)
|
—
est: 2.50M (-100.0%)
|
—
est: 2.60M (-100.0%)
|
28.0K
est: 5.00M (-99.4%)
|
4.40M
30.6K – 10.21M
-12.0% YoY
|
13.49M
5.18M – 18.30M
+206.6% YoY
|
33.77M
33.64M – 33.90M
+150.2% YoY
|
44.48M
13.02M – 70.71M
+31.7% YoY
|
223.00M
65.26M – 354.48M
+401.3% YoY
|
| EBITDA |
-16.40M
est: 600.0K (-2,832.8%)
|
-10.51M
est: 1.50M (-800.5%)
|
-13.96M
est: 1.56M (-994.6%)
|
-16.21M
est: 3.00M (-640.4%)
|
2.64M
18.4K – 6.13M
-12.0% YoY
|
8.10M
3.11M – 10.98M
+206.6% YoY
|
20.26M
20.18M – 20.34M
+150.2% YoY
|
26.69M
7.81M – 42.42M
+31.7% YoY
|
133.80M
39.16M – 212.69M
+401.3% YoY
|
| EBIT |
-16.60M
est: 600.0K (-2,866.5%)
|
-11.06M
est: 1.50M (-837.3%)
|
-14.36M
est: 1.56M (-1,020.4%)
|
-16.62M
est: 3.00M (-653.9%)
|
2.64M
18.4K – 6.13M
-12.0% YoY
|
8.10M
3.11M – 10.98M
+206.6% YoY
|
20.26M
20.18M – 20.34M
+150.2% YoY
|
26.69M
7.81M – 42.42M
+31.7% YoY
|
133.80M
39.16M – 212.69M
+401.3% YoY
|
| Net Income |
-17.16M
est: -19.39M (+11.5%)
|
-11.14M
est: -15.97M (+30.3%)
|
-14.00M
est: -15.97M (+12.3%)
|
-16.41M
est: -13.85M (-18.5%)
|
-11.82M
-14.33M – -9.31M
+14.6% YoY
|
-7.03M
-9.38M – -4.69M
+40.5% YoY
|
-1.23M
-2.37M – 157.9K
+82.5% YoY
|
5.43M
436.9K – 9.60M
+540.5% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
10.68M
est: 23.01M (-53.6%)
|
6.91M
est: 57.54M (-88.0%)
|
972.0K
est: 59.84M (-98.4%)
|
3.11M
est: 115.07M (-97.3%)
|
101.28M
705.0K – 235.00M
-12.0% YoY
|
310.57M
119.23M – 421.21M
+206.6% YoY
|
777.12M
774.16M – 780.07M
+150.2% YoY
|
1.02B
299.58M – 1.63B
+31.7% YoY
|
5.13B
1.50B – 8.16B
+401.3% YoY
|
| EPS |
-0.26
est: -0.21 (-23.8%)
|
-0.14
est: -0.17 (+19.1%)
|
-0.18
est: -0.17 (-4.0%)
|
-0.18
est: -0.15 (-20.0%)
|
-0.13
-0.16 – -0.10
+16.2% YoY
|
-0.08
-0.10 – -0.05
+36.4% YoY
|
-0.01
-0.03 – 0.00
+85.0% YoY
|
0.06
0.00 – 0.10
+591.5% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.67M
OE per share TTM
-0.08
Owner's Yield
-1.71%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
28,211.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-3.9K
Shares Outstanding
113.80M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Konstantopoulos | Co-Founder & Chief Executive Officer | 287.5K | male |
| Bernard William Ridgeway | Executive Chair | 111.5K | male |
| Mark Edward Pitts | Company Secretary | — | male |
| Phil Bowen | Chief Operations Officer | — | — |
| Richard Mark Jarvis | Chief Financial Officer | — | male |
| Richard Stewart | Chief Regulatory Affairs & Quality Officer | — | — |
| Ryan Athearn | Head of Global Clinical Operations | — | — |
| Girish Dwivedi | Chief Scientific Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AYA.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
